$333 Million is the total value of ProQuest Associates IV LLC's 4 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EGRX | Sell | EAGLE PHARMACEUTICALS, INC. | $302,920,000 | -3.4% | 3,652,284 | -7.6% | 91.10% | +2.6% |
| AGRX | AGILE THERAPEUTICS, INC. | $16,250,000 | -43.7% | 5,062,363 | 0.0% | 4.89% | -40.2% | |
| IMDZ | IMMUNE DESIGN CORP. | $13,346,000 | +23.6% | 1,962,720 | 0.0% | 4.01% | +31.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGILE THERAPEUTICS, INC. | 16 | Q3 2018 | 24.3% |
| IMMUNE DESIGN CORP. | 16 | Q3 2018 | 42.1% |
| EAGLE PHARMACEUTICALS, INC. | 15 | Q2 2018 | 91.1% |
| ANTHERA PHARMACEUTICALS INC. | 8 | Q3 2016 | 3.4% |
| UROGEN PHARMA LTD. | 6 | Q3 2018 | 70.4% |
| MERSANA THERAPEUTICS, INC. | 6 | Q3 2018 | 26.3% |
| MAST THERAPEUTICS, INC. | 5 | Q4 2015 | 0.7% |
| ZOSANO PHARMA CORP. | 3 | Q3 2015 | 0.8% |
| ACHILLION PHARMACEUTICALS, INC. | 1 | Q4 2014 | 7.0% |
View ProQuest Associates IV LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 4 | 2017-11-29 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 3 | 2017-07-20 |
| 13F-HR | 2017-05-15 |
| 4 | 2017-05-15 |
View ProQuest Associates IV LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.